Archive for January 2011

Aspen granted generic license for the manufacture and supply of TMC278

Johannesburg. Aspen (APN), South Africa’s leading pharmaceutical company, has announced that Irish-based Tibotec Pharmaceuticals has granted it a non-exclusive license to manufacture, market and distribute the Anti-retroviral (“ARV”) compound, rilpivirine hydrochloride (TMC278), pending approval of the molecule which could then be prescribed for patients commencing ARV treatment for the first time as well as for…

Read More

Aspen acquires Sigma’s pharmaceutical business for R6,1 billion

ASPEN ACQUIRES SIGMA’S PHARMACEUTICAL BUSINESS FOR R6,1 BILLION Johannesburg. Aspen (APN), South Africa’s leading pharmaceutical company, has announced that all conditions precedent have been met for it to acquire the pharmaceutical business of Australian-based Sigma Pharmaceuticals Limited (“Sigma”). The acquisition was approved following the extraordinary meeting of Sigma shareholders held on 14 January 2011. The…

Read More